Predix Pharmaceuticals prepares for public offering

Predix Pharmaceuticals, which has facilities in Lexington, Massachusetts, and Israel, has filed to go public. The company raised $43 million in its third round of venture capital last January. Researchers at Predix are investigating compounds for general anxiety disorder, hypertension and Alzheimer's.

- read this report from Globes for more

Suggested Articles

A phase 3 study of NuCana’s lead drug was halted because a monitoring committee deemed it unlikely to succeed.

The filing follows data from Japanese phase 3 trials that assessed the oral HIF-PHI in chronic kidney disease patients.

The Allen Institute found major differences in human and mouse brain cells, which could guide the design of drugs for brain diseases.